This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Antares Announces Podium Presentation Of Pivotal OTREXUP™ (methotrexate) Data At American College Of Rheumatology Annual Meeting

Stocks in this article: ATRS

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, oral presentation during a clinical treatment strategies sub-session of the 2013 American College of Rheumatology (ACR) Annual Meeting, in San Diego.

The abstract, entitled “Drug exposure limitations of oral methotrexate (MTX) at doses ≥15mg may be overcome by using a subcutaneous MTX auto-injector in patients with rheumatoid arthritis (RA),” was among a select group of key abstracts awarded the distinction of a live, oral presentation. In addition to the oral presentation, data from two other Antares-supported clinical studies were accepted for presentation at the ACR meeting as scientific posters.

The clinical study data that will be presented live are from a randomized, open-label, three-way crossover study comparing the systemic availability of methotrexate using the OTREXUP™ self-administration device-drug combination compared with methotrexate taken orally.

“We are pleased that the ACR included our pivotal OTREXUP™ data as an oral presentation at the premier rheumatology medical meeting in the United States,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “We believe these data represent a significant step forward in addressing an unmet need in the current standard of care and may provide support for extending the use of methotrexate in rheumatoid arthritis patients.”

The details for Antares’ oral presentation are as follows:

Date & Time: Sunday, October 27 from 2:30-2:45 p.m. PT

Location: Hall 6F

Abstract Number: 796

Poster Title: Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in patients with rheumatoid arthritis (RA)

Presenter: Michael H Schiff, M.D., University of Colorado, Denver

The details for Antares’ poster presentations are as follows:

Date & Time: Monday, October 28 from 9:00–11:00 a.m. PT

Location: Poster Hall

Abstract Number: 1337

Poster Title: Nearly pain free self-administration of methotrexate (MTX) using an investigational auto-injector: Results of a phase-2 clinical trial in rheumatoid arthritis (PA) patients with mild-to-severe functional limitations

Presenter: Alan Kivitz, M.D., Altoona Center for Clinical Research, Duncansville, PA

Date & Time: Tuesday, October 29 from 9:00-11:00 a.m. PT

Location: Poster Hall

Abstract Number: 2313

Poster Title: Pain-related anxiety as a barrier to use of subcutaneous (SC) methotrexate (MTX) in rheumatoid arthritis (RA): Comparing conventional vial, needles, and syringe (VNS) with an investigational auto-injector (AI) in healthy volunteers

Presenter: Victoria Ruffing, RN, CCRN, Johns Hopkins Arthritis Center Johns Hopkins University, Baltimore, MD

For full prescribing information please visit WWW.OTREXUP.COM


OTREXUP is a single-dose auto-injector containing a prescription medicine, methotrexate. Methotrexate is used to:

  • treat certain adults with severe, active rheumatoid arthritis (RA), and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory (NSAIDS) have been used and did not work well.
  • control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.

OTREXUP should not be used for the treatment of cancer.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs